Windtree Therapeutics, Inc.

NasdaqCM:WINT Stock Report

Market Cap: US$6.3m

Windtree Therapeutics Management

Management criteria checks 3/4

Windtree Therapeutics' CEO is Craig Fraser, appointed in Feb 2016, has a tenure of 8.75 years. total yearly compensation is $693.63K, comprised of 80.3% salary and 19.7% bonuses, including company stock and options. directly owns 0.099% of the company’s shares, worth $6.23K. The average tenure of the management team and the board of directors is 4.5 years and 0.8 years respectively.

Key information

Craig Fraser

Chief executive officer

US$693.6k

Total compensation

CEO salary percentage80.3%
CEO tenure8.8yrs
CEO ownership0.1%
Management average tenure4.5yrs
Board average tenureless than a year

Recent management updates

Recent updates

Windtree Therapeutics CEO Craig Fraser - Breaking Down Acute Heart Failure (Video)

Dec 06

Windtree Therapeutics: Addressing Underserved And Expensive Acute Conditions

Jul 06

Shareholders Will Likely Find Windtree Therapeutics, Inc.'s (NASDAQ:WINT) CEO Compensation Acceptable

Jun 09
Shareholders Will Likely Find Windtree Therapeutics, Inc.'s (NASDAQ:WINT) CEO Compensation Acceptable

Should You Take Comfort From Insider Transactions At Windtree Therapeutics, Inc. (NASDAQ:WINT)?

Feb 09
Should You Take Comfort From Insider Transactions At Windtree Therapeutics, Inc. (NASDAQ:WINT)?

CEO Compensation Analysis

How has Craig Fraser's remuneration changed compared to Windtree Therapeutics's earnings?
DateTotal CompensationSalaryCompany Earnings
Jun 30 2024n/an/a

-US$11m

Mar 31 2024n/an/a

-US$6m

Dec 31 2023US$694kUS$557k

-US$20m

Sep 30 2023n/an/a

-US$25m

Jun 30 2023n/an/a

-US$24m

Mar 31 2023n/an/a

-US$35m

Dec 31 2022US$941kUS$545k

-US$39m

Sep 30 2022n/an/a

-US$43m

Jun 30 2022n/an/a

-US$47m

Mar 31 2022n/an/a

-US$67m

Dec 31 2021US$2mUS$480k

-US$68m

Sep 30 2021n/an/a

-US$62m

Jun 30 2021n/an/a

-US$63m

Mar 31 2021n/an/a

-US$35m

Dec 31 2020US$770kUS$460k

-US$33m

Sep 30 2020n/an/a

-US$32m

Jun 30 2020n/an/a

-US$31m

Mar 31 2020n/an/a

-US$27m

Dec 31 2019US$1mUS$452k

-US$27m

Sep 30 2019n/an/a

-US$43m

Jun 30 2019n/an/a

-US$40m

Mar 31 2019n/an/a

-US$37m

Dec 31 2018US$5mUS$437k

-US$35m

Sep 30 2018n/an/a

-US$9m

Jun 30 2018n/an/a

-US$13m

Mar 31 2018n/an/a

-US$17m

Dec 31 2017US$641kUS$425k

-US$25m

Compensation vs Market: Craig's total compensation ($USD693.63K) is about average for companies of similar size in the US market ($USD655.65K).

Compensation vs Earnings: Craig's compensation has been consistent with company performance over the past year.

CEO

Craig Fraser (59 yo)

8.8yrs

Tenure

US$693,625

Compensation

Mr. Craig E. Fraser is Chairman of the Board at Windtree Therapeutics, Inc. since June 22, 2023. He has been Chief Executive Officer and President of Windtree Therapeutics, Inc. since February 1, 2016 and...

Leadership Team

NamePositionTenureCompensationOwnership
Craig Fraser
President8.8yrsUS$693.63k0.099%
$ 6.2k
Eric Curtis
Senior VP & COO4.7yrsUS$451.73k0.00048%
$ 30.3
Steven Simonson
Senior VP & Chief Medical Officer10.1yrsUS$491.73k0.00070%
$ 44.1
Jamie McAndrew
Senior VP1.3yrsno data0.0065%
$ 410.5
George Cox
Vice President of Technical Operationsno datano datano data
Pratap Paruchuru
Executive Director of Clinical Development4.3yrsno datano data
Tracy Rarick
Head of Operations & Program Management4.3yrsno datano data

4.5yrs

Average Tenure

59yo

Average Age

Experienced Management: WINT's management team is considered experienced (4.5 years average tenure).

Board Members

NamePositionTenureCompensationOwnership
Craig Fraser
President8.8yrsUS$693.63k0.099%
$ 6.2k
Mark Strobeck
Lead Independent Director1.4yrsUS$32.34kno data
Saundra Pelletier
Independent Directorless than a yearno datano data
Jed Latkin
Independent Directorless than a yearno datano data

0.8yrs

Average Tenure

53.5yo

Average Age

Experienced Board: WINT's board of directors are not considered experienced ( 0.8 years average tenure), which suggests a new board.